Making an RNA Detour Around an Undruggable Target
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Making an RNA Detour Around an Undruggable Target
-
Narrated by:
-
By:
Summary
Some cancer-driving proteins offer few ways for conventional drugs to target, leaving patients with limited options even when researchers understand what fuels their tumors. Remix Therapeutics is approaching that problem by developing oral small molecules that alter RNA processing to reduce production of those proteins. Pete Smith, co-founder and CEO of Remix, discusses the company’s experimental MYB-targeting therapy, the early evidence in adenoid cystic carcinoma, and whether changing how cells process RNA could open a new route to previously elusive cancer targets.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.